Daily Endocrinology Research Analysis
Analyzed 83 papers and selected 3 impactful papers.
Summary
Three papers stood out in endocrinology: a comprehensive BMJ network meta-analysis compared 19 anti-obesity drugs across 262 trials, quantifying weight-loss benefits, safety trade-offs, and limited quality-of-life gains. A JCI longitudinal study showed menopause transition is associated with sustained increases in markers of gut barrier compromise, translating a mechanism previously seen in animals to humans. An analysis of DCCT data in Diabetes Care linked detectable C-peptide to a markedly lower risk of diabetic ketoacidosis in type 1 diabetes, underscoring the value of beta-cell preservation.
Research Themes
- Comparative effectiveness and safety of anti-obesity pharmacotherapy
- Menopause-associated gut barrier dysfunction and systemic inflammation
- Endogenous insulin preservation and ketoacidosis risk in type 1 diabetes
Selected Articles
1. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Across 262 randomized trials, tirzepatide and cagrilintide-semaglutide produced the greatest one-year weight loss (~15%) but with higher discontinuation due to adverse events; gastrointestinal events and fatigue were common for several agents. Subcutaneous semaglutide uniquely reduced all-cause mortality and myocardial infarction, while overall quality-of-life gains were generally below minimally important differences.
Impact: This work provides the most comprehensive, methodologically rigorous comparison of modern anti-obesity drugs, quantifying benefit–harm trade-offs and identifying rare hard outcome signals.
Clinical Implications: Shared decision-making should weigh greater weight loss against higher discontinuation risks; subcutaneous semaglutide has the strongest evidence for cardiovascular benefit. Routine QOL improvement should not be assumed, and monitoring for GI adverse events and fatigue is essential.
Key Findings
- At 1 year, tirzepatide (−14.9%) and cagrilintide-semaglutide (−14.8%) achieved the largest mean percent weight loss versus lifestyle alone.
- Discontinuation due to adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (RR ~1.9–4.2).
- Subcutaneous semaglutide reduced all-cause mortality (RR 0.81) and myocardial infarction (RR 0.72); tirzepatide and subcutaneous semaglutide reduced heart failure risk.
- Quality-of-life improvements did not exceed minimally important differences across agents in pooled analyses.
Methodological Strengths
- Large-scale network meta-analysis of 262 RCTs with GRADE and ROB2 assessments
- Dose–response modeling (Bayesian) and frequentist random-effects synthesis across 24 outcomes
Limitations
- Sparse networks for newer agents and reliance on indirect comparisons for some contrasts
- Heterogeneity in trial populations and durations; limited patient-reported outcomes reaching minimally important differences
Future Directions: Head-to-head RCTs for leading agents, longer-term effectiveness and safety including maintenance after discontinuation, and standardized quality-of-life and function outcomes.
OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. DESIGN: Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. DATA SOURCES: Medline, Embase, and Cochrane Library, searched up to 12 November 2025. STUDY SELECTION: Randomised controlled trials of 12 weeks' duration or longer comparing one or more drugs with lifestyle modification, placebo, or another drug. RESULTS: This network meta-analysis comprised 262 trials (99 791 participants) evaluating 19 drugs with follow-up from 12 to 172 weeks. Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%). Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty). Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particularly with naltrexone-bupropion (risk ratio 8.9; absolute increase 331 per 1000 people over one year), orforglipron (3.4; 100 more per 1000), and CagriSema (3.2; 92 more per 1000). Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%). Subcutaneous semaglutide was the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93) and myocardial infarction (0.72, 0.61 to 0.85), with these estimates largely informed by cardiovascular outcome trials in high risk populations. Subcutaneous semaglutide (0.43, 0.21 to 0.84) and tirzepatide (0.49, 0.27 to 0.88) reduced heart failure risk. No drugs convincingly reduced kidney failure or improved quality of life (43 trials with 45 663 participants) beyond established minimally important differences (all mean differences <5 points; minimally important difference 10). Except for larger weight reductions in trials with longer duration (shown for subcutaneous semaglutide), subgroup analyses for drug dosages and key patient characteristics did not identify credible differences in relative effects of treatment. CONCLUSIONS: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024507993.
2. Markers of compromised gut epithelial barrier integrity increase during the menopause transition.
In 964 women followed across the menopause transition, serum FABP2 (epithelial injury) and sCD14 (microbial translocation) rose beginning ~2.5 years before and ~2 years before the final menstrual period, peaking ~6–6.5 years after. Rates of increase were consistent across race/ethnicity, BMI, and age at FMP, supporting a human link between menopause transition and gut barrier compromise.
Impact: This is among the first human longitudinal demonstrations that menopause transition is accompanied by sustained increases in gut barrier dysfunction markers, translating animal findings to human physiology.
Clinical Implications: These findings suggest a potential inflammatory pathway during menopause that may contribute to metabolic and skeletal changes, motivating trials to test gut-targeted or anti-inflammatory interventions during the transition.
Key Findings
- FABP2 began increasing ~2.5 years prior to FMP; sCD14 began increasing ~6 months later.
- Markers peaked at ~6.0 (FABP2) and 6.5 (sCD14) years post-FMP and then stabilized.
- Annual increases during the ~9-year interval were 2.6% for FABP2 and 0.8% for sCD14 among reference participants.
- Rise rates did not differ by race/ethnicity, BMI, or age at FMP.
Methodological Strengths
- Large longitudinal cohort with repeated measures anchored to the final menstrual period
- Piece-wise mixed-effects modeling with adjustment for key covariates
Limitations
- Biomarkers reflect systemic signals of barrier compromise but not direct permeability tests
- Causality and clinical endpoints (e.g., fractures, cardiometabolic disease) were not assessed
Future Directions: Interventional trials targeting the gut barrier/microbiome during menopause transition and integration with clinical outcomes (bone, cardiometabolic, symptoms).
BACKGROUND: In female murine models, one source of inflammation is a menopause-related increase in gut permeability. We examined whether the menopause transition (MT) in women is associated with an increase in markers of gut epithelial dysfunction and gut microbial product translocation, signals of compromised gut epithelial barrier integrity. METHODS: In 964 women, we measured markers of gut epithelial dysfunction (fatty acid binding protein 2, FABP2) and gut microbial antigen translocation (soluble CD14, sCD14) using sera collected before, during and after the MT. Multivariable mixed effects regressions fit piece-wise linear models to repeated FABP2 or sCD14 measures relative to time from final menstrual period (FMP). Covariates were age at FMP, race/ethnicity, and BMI. RESULTS: FABP2 and sCD14 did not change significantly until 2.5 years pre-FMP. At that point, FABP2 began rising; sCD14 began increasing 6 months later. FABP2 and sCD14 peaked 6 and 6.5 years post-FMP, respectively; subsequent levels remained stable. During the ~9-year interval of MT-related gain in gut barrier compromise markers, annual FABP2 and sCD14 increases were 2.6% (95% CI: 1.7 to 3.4%) and 0.8% (95% CI: 0.6 to 1.1%), respectively, among white women with sample-average BMI and age at FMP. FABP2 and sCD14 change rates did not differ significantly by race/ethnicity, BMI, or age at FMP. CONCLUSIONS: The MT is associated with a rise in markers of compromised gut barrier integrity, suggesting that this pathway of inflammation, previously described in animal models, occurs in humans. FUNDING: NIH U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495, 5R01AR081794.
3. Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes.
In the DCCT cohort (n=1,441) over 6.5 years, 99.4% of DKA events occurred when prior-year stimulated C-peptide was ≤0.2 nmol/L; detectable C-peptide >0.2 nmol/L was associated with a 93% lower DKA hazard. The association was robust across adjusted recurrent event models.
Impact: Provides quantitative evidence that residual beta-cell function confers substantial protection against DKA, reinforcing the rationale for disease-modifying therapies aiming to preserve endogenous insulin.
Clinical Implications: Monitoring stimulated C-peptide can risk-stratify for DKA and support prioritizing immunomodulatory or beta-cell–preserving interventions; even modest endogenous insulin production may have meaningful protective effects.
Key Findings
- Among 180 DKA events, 179 (99.44%) occurred after prior-year C-peptide ≤0.2 nmol/L; only 1 event occurred with >0.2 nmol/L.
- Detectable stimulated C-peptide >0.2 nmol/L was associated with HR 0.07 (95% CI 0.01–0.48) for DKA.
- Findings were consistent across crude and adjusted Andersen–Gill recurrent event models with time-dependent covariates.
Methodological Strengths
- Use of a well-characterized, prospective DCCT dataset with adjudicated outcomes
- Time-to-event modeling for recurrent events with time-dependent covariates
Limitations
- Post hoc secondary analysis; generalizability beyond DCCT-era management may be limited
- Stimulated C-peptide measured annually may miss shorter-term fluctuations
Future Directions: Prospective validation in contemporary cohorts and trials testing whether beta-cell–preserving interventions reduce long-term DKA incidence.
OBJECTIVE: To investigate whether detectable C-peptide levels in type 1 diabetes is associated with a lower risk of diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: We analyzed the Diabetes Control and Complications Trial publicly available data repository for the association between detectable stimulated C-peptide (>0.2 nmol/mL, measured annually) and DKA incidence over an average 6.5-year follow-up. We used crude and adjusted Andersen-Gill models for recurrent DKA events with time-dependent covariates. RESULTS: Of the 1,441 participants (53% male, median age 27 years), 129 (9%) experienced 180 DKA events. Of these events, 179 (99.44%) occurred after C-peptide was ≤0.2 nmol/L in the prior year and only 1 event occurred with C-peptide >0.2 nmol/L. C-peptide >0.2 nmol/L was associated with a DKA hazard ratio of 0.07 (95% CI 0.01-0.48; P = 0.007), consistent across adjusted models. CONCLUSIONS: Endogenous insulin production was significantly associated with lower DKA risk, suggesting that treatments preserving insulin production could decrease long-term DKA risk.